AKT1 and breast carcinoma: Since the PI3K–AKT–FOXO axis is highly active in the development of breast cancer drug-resistance and PARP12 is a positive regulator of this pathway, we propose PARP12 as potential pharmacological target to be exploited to re-sensitize ER + breast cancer to endocrine treatment.